Strata Wealth Advisors LLC Has $666,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Strata Wealth Advisors LLC boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 83.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,016 shares of the company's stock after purchasing an additional 1,827 shares during the quarter. Strata Wealth Advisors LLC's holdings in Johnson & Johnson were worth $666,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $29,000. Conquis Financial LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in Johnson & Johnson during the fourth quarter valued at approximately $38,000. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on JNJ shares. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Morgan Stanley reissued an "underperform" rating on shares of Johnson & Johnson in a research note on Thursday, July 10th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded down $1.44 during midday trading on Tuesday, reaching $155.38. 6,860,493 shares of the company were exchanged, compared to its average volume of 8,087,019. The stock's 50-day moving average price is $153.79 and its 200-day moving average price is $154.63. The stock has a market cap of $373.86 billion, a P/E ratio of 17.28, a PEG ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.